Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology (ASH) Annual Meeting

- LP-284 demonstrated distinct anti-tumor activity in hematologic cancer cells - LP-284 exhibited potency in lymphoma, multiple myeloma, and leukemia cell lines - Data supports potential development in important new rare blood cancer indications

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here